STOCK TITAN

Tekla World Healthcare Fund Declares Monthly Cash Distribution

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Neutral)
Tags

On April 9, 2021, Tekla World Healthcare Fund declared its monthly cash distribution of $0.1167 per share. The record date for the monthly cash distribution is April 20, 2021 and the payable date is April 30, 2021. The Fund will trade ex-distribution on April 19, 2021.

Note that only participants in the Fund’s Dividend Reinvestment and Stock Purchase Plan (“DRIP”) will have cash distributions automatically reinvested in shares of the Fund.

Tekla World Healthcare Fund (NYSE: THW) is a closed-end fund that invests in companies in the healthcare industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund. Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.

Information regarding the Fund and Tekla Capital Management LLC can be found at www.teklacap.com.

Please contact Destra Capital Advisors, the Fund’s marketing and investor support services agent, at THW@destracapital.com or call (877)855-3434 if you have any questions regarding THW.

abrdn World Healthcare Fund

NYSE:THW

THW Rankings

THW Latest News

THW Stock Data

491.44M
38.00M
0%
11.83%
0.75%
Asset Management
Financial Services
Link
United States of America
Boston

About THW

tekla life sciences investors is a closed-ended equity mutual fund launched and managed by tekla capital management llc. the fund invests in public equity markets across the globe. it seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. the fund primarily invests in growth stocks of small cap companies. it employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. the fund benchmarks the performance of its portfolio against the nasdaq biotech index and the s&p 500 index. it was form